Paclitaxel and Mortality: Where Are We now?

Christopher P Twine; Hasan H Dosluoglu

doi:10.1016/j.ejvs.2020.03.012

Paclitaxel and Mortality: Where Are We now?

Christopher P Twine^*, Hasan H Dosluoglu

^*Corresponding author for this work

Bristol Medical School (PHS)

Research output: Contribution to journal › Comment/debate (Academic Journal)

3 Citations (Scopus)

71 Downloads (Pure)

Abstract

The high quality adjusted case series by Saratzis et al. 1 puts another strong counter argument to the paclitaxel increases mortality debate started by the meta-analysis from Katsanos et al. in 2018. 2 The reaction to that meta-analysis was unprecedented in recent times, halting international practice despite widespread adoption of the technology and derailing randomised trials.

Original language	English
Number of pages	1
Journal	European Journal of Vascular and Endovascular Surgery
Early online date	4 Apr 2020
DOIs	https://doi.org/10.1016/j.ejvs.2020.03.012
Publication status	E-pub ahead of print - 4 Apr 2020

Access to Document

10.1016/j.ejvs.2020.03.012

Full-text PDF (author accepted manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://www.ejves.com/article/S1078-5884(20)30240-9/fulltext#articleInformation. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 74.3 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{ffb12ee392504705a21db21d58564ac1,

title = "Paclitaxel and Mortality: Where Are We now?",

abstract = "The high quality adjusted case series by Saratzis et al. 1 puts another strong counter argument to the paclitaxel increases mortality debate started by the meta-analysis from Katsanos et al. in 2018. 2 The reaction to that meta-analysis was unprecedented in recent times, halting international practice despite widespread adoption of the technology and derailing randomised trials. ",

author = "Twine, {Christopher P} and Dosluoglu, {Hasan H}",

year = "2020",

month = apr,

day = "4",

doi = "10.1016/j.ejvs.2020.03.012",

language = "English",

journal = "European Journal of Vascular and Endovascular Surgery",

issn = "1078-5884",

publisher = "W.B. Saunders",

}

TY - JOUR

T1 - Paclitaxel and Mortality

T2 - Where Are We now?

AU - Twine, Christopher P

AU - Dosluoglu, Hasan H

PY - 2020/4/4

Y1 - 2020/4/4

N2 - The high quality adjusted case series by Saratzis et al. 1 puts another strong counter argument to the paclitaxel increases mortality debate started by the meta-analysis from Katsanos et al. in 2018. 2 The reaction to that meta-analysis was unprecedented in recent times, halting international practice despite widespread adoption of the technology and derailing randomised trials.

AB - The high quality adjusted case series by Saratzis et al. 1 puts another strong counter argument to the paclitaxel increases mortality debate started by the meta-analysis from Katsanos et al. in 2018. 2 The reaction to that meta-analysis was unprecedented in recent times, halting international practice despite widespread adoption of the technology and derailing randomised trials.

U2 - 10.1016/j.ejvs.2020.03.012

DO - 10.1016/j.ejvs.2020.03.012

M3 - Comment/debate (Academic Journal)

C2 - 32265112

SN - 1078-5884

JO - European Journal of Vascular and Endovascular Surgery

JF - European Journal of Vascular and Endovascular Surgery

ER -

Paclitaxel and Mortality: Where Are We now?

Abstract

Access to Document

Handle.net

Fingerprint

Cite this